TherapeuticsMD
TXMD
128 hedge funds and large institutions have $980M invested in TherapeuticsMD in 2016 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 66 increasing their positions, 26 reducing their positions, and 15 closing their positions.
154% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 26
93% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $1.76M
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
4% more funds holding
Funds holding: 123 → 128 (+5)
0.12% more ownership
Funds ownership: 1.44% → 1.56% (+0.12%)
26% less capital invested
Capital invested by funds: $1.33B → $980M (-$349M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$71.5M |
| 2 |
JP Morgan Chase
New York
|
+$25.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.8M |
| 5 |
Bank of New York Mellon
New York
|
+$7.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$5.49M |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$5.28M |
| 3 |
Millennium Management
New York
|
-$4.85M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.77M |
| 5 |
AI
Analytic Investors
Los Angeles,
California
|
-$1.49M |
TXMD Hedge Fund Activity: Q1 2016 in Review
128 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2016, worth a combined $980M — down 26% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TXMD positions and 15 closed out — a net gain of 6 holders — while 66 added to existing stakes and 26 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $71.5M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $5.49M sold.
- 128 institutional investors held TherapeuticsMD (TXMD) as of Q1 2016, up from 123 in Q4 2015.
- Funds reported $980M of TherapeuticsMD stock for Q1 2016, down 26% quarter-over-quarter.
- 21 funds opened new TherapeuticsMD positions in Q1 2016 and 15 closed out, a net change of +6 holders.
- The largest TherapeuticsMD buyer in Q1 2016 was T. Rowe Price Associates, an estimated $71.5M added.
- The largest TherapeuticsMD seller in Q1 2016 was Renaissance Technologies, an estimated $5.49M sold.
Based on aggregated 13F filings for Q1 2016.